

# **OPPI Coverage Dossier**


## **May 2025**

## INDEX

S.no	Date	Publication	Edition	Link
Online				
1	17 May	ET pharma	Online	<a href="#">Natura Non Facit Saltum: Incremental Innovation in Pharmaceuticals</a>
2	5 May	Scrip	Online	<a href="#">OPPI's Matai On Section 3(d) Of India's Patent Regulations: Now's The Time To Open Up</a>







**ONLINE**


Publication	ET pharma
Date	17 May
Edition	Online
Headline	<a href="#">Natura Non Facit Saltum: Incremental Innovation in Pharmaceuticals</a>



[News](#)
[Exclusives](#)
[Leaders Speak](#)
[Events](#)
[Webinars](#)
[Brand Solutions](#)
[More](#)

## Natura Non Facit Saltum: Incremental Innovation in Pharmaceuticals

Globally, patent systems acknowledge and encourage such stepwise innovation. Under frameworks like the TRIPS Agreement, patents are granted for inventions that are novel, involve an inventive step, and are industrially applicable.


**Anil Matai** • ET Pharma  
 Updated On May 17, 2025 at 11:41 AM IST



The Latin phrase *Natura non facit saltum*, meaning “nature does nothing in leaps,” captures the essence of how progress unfolds in the world and nowhere is this more evident than in pharmaceuticals.

Scientific advancement, particularly in drug discovery and development, rarely comes in the form of sudden, groundbreaking discoveries.

<b>Publication</b>	Scrip
<b>Date</b>	5 May
<b>Edition</b>	Online
<b>Headline</b>	<a href="#">OPPI's Matai On Section 3(d) Of India's Patent Regulations: Now's The Time To Open Up</a>

## OPPI's Matai On Section 3(d) Of India's Patent Regulations: Now's The Time To Open Up

Industry Group's Head Shares Views In Audio Interview

05 May 2025 • By [Anju Ghangurde](#)

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India's patent regulations and innovator firms' experience of the Bolar provision. There's also a "compelling reason" to consider regulatory data protection, he claims.



(OPPI)

"The needle has moved," declares Anil Matai, director general of the Organization of Pharmaceutical Producers of India (OPPI), describing India's evolving intellectual property rights regime, which saw the